Related Experiment Videos
Treatment of chronic typhoid carriers with ampicillin
Antimicrobial Agents and Chemotherapy
|March 1, 1973
Abstract:
Ten chronic enteric typhoid carriers treated with oral ampicillin have been followed for 4 to 9 years and no relapses have occurred. Patients are probably cured if relapse does not occur within 2 years.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Predicting Patient Status in Chronic Thromboembolic Pulmonary Hypertension Using a Biophysical Model.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2023
Clinical risk prediction model for 30-day all-cause re-hospitalisation or mortality in patients hospitalised with heart failure.
International journal of cardiology·2022
The impact of HIV/AIDS stigma on HIV counseling and testing in a high HIV prevalence population in Uganda.
African health sciences·2013
L2 β-lactamase contributes to ceftolozane-tazobactam resistance in Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy·2026
Phage-first treatment results in subpopulation-driven collateral sensitivity to beta-lactams in an extensively drug-resistant Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy·2026
Population pharmacokinetics of piperacillin/tazobactam in critically ill pediatric patients.
Antimicrobial agents and chemotherapy·2026
XAB06, a glyco-humanized broad-spectrum anti-Pseudomonas aeruginosa polyclonal antibody, protects mice in a lethal sepsis model.
Antimicrobial agents and chemotherapy·2026
In vitro activity profiles and temporal trends in reduced susceptibility to azoles in Coccidioides in the United States.
Antimicrobial agents and chemotherapy·2026
Post-diagnosis cannabis use and its association with health status and quality of life in cancer survivors.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Aloesin mitigates cisplatin-induced nephrotoxicity by suppressing NF-κB-mediated oxidative stress and modulating Bax/Bcl-2/caspase pathways.
Naunyn-Schmiedeberg's archives of pharmacology·2026